Ovid and Takeda create a one-team strategy to steer a neuro drug to the world
Jeremy Levin’s team at Ovid Therapeutics has been scouring the globe for new drugs to treat orphan brain diseases. And after spending a year in discussions with a fast-changing Takeda, the little biotech and large pharma organization are bonding on a tightly knit partnership aimed at jointly advancing an early-stage program for rare epileptic encephalopathies that will see Ovid build a new group operation in Cambridge, MA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.